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TO THE EDITOR Generalized pustular psoriasis (GPP) is a rare disorder affecting about 2 per million individuals in Europe (Augey et al., 2006) . This severe disease is characterized by repeated flare-ups of pustules and can be accompanied by a potentially life-threatening multisystemic inflammation. Recently, missense mutations in IL36RN have been identified in GPP patients from Tunisia and Europe (Marrakchi et al., 2011; Onoufriadis et al., 2011) . In addition, a stop mutation, a novel missense mutation, and mutations affecting splicing of exon 3 have been observed in Japanese patients (Sugiura et al., 2012; Farooq et al., 2013) . IL36RN's product IL36RA antagonizing three cytokines of the IL1-family (Blumberg et al., 2010) and therapy with a recombinant interleukin-1 receptor antagonist (anakinra) being effective in some GPP patients (Viguier et al., 2010) independently support the role of IL36RN as a disease-causing gene.
A group of 19 patients were recruited at five German university hospitals and one specialized dermatology hospital. In all, 17 patients suffered from typical symptoms of GPP, one patient from psoriasis vulgaris (PsV) with repeated flares of generalized grouped pustules without fever (ID P18, Table 1 ), and another one from PsV with pustules (P19). The study, approved by the ethical committee of the University of Erlangen, was conducted according to the Declaration of Helsinki principles.
All patients/legal guardians gave written informed consent. Patients were screened for mutations in coding exons 2-5 of IL36RN by Sanger sequencing; mutations were named according to reference sequence NM_173170. In cases of no point mutation/homozygous mutations without available parents, MLPA (multiplex ligation-dependent probe amplification, MRC Holland, (Schouten et al., 2002) ) as a quantitative analysis was performed with selfdesigned oligonucleotides for coding exons. The three-dimensional structure of human IL36RA was modeled with SwissModel (Guex et al., 2009 ) using the high-resolution crystal structure of murine IL-1F5 as a template (PDB code: 1MD6; Dunn et al., 2003) . Promising variants possibly affecting the structure of IL36RA were generated with SwissModel (Guex et al., 2009) , selecting the lowestenergy rotamer for each mutated side chain. Structure analysis and visualization was performed with RasMol (Sayle and Milner-White, 1995) .
The majority of GPP patients were female (68.4%; Table 1 ). We identified homozygous/compound heterozygous variants in seven patients: four patients were homozygous for p.His32Arg, p.Pro76Leu, or p.Ser113Leu, and three further individuals were compound heterozygous for p.Ser113Leu and either p.Arg48Trp, p.Glu94X, or p.Pro76Leu. The stop mutation and the two missense variants p.His32Arg and p.Pro76Leu were, to our knowledge, previously unreported, all affecting highly conserved residues. p.Glu94X disrupted the globular cytokine fold ( Figure 1b ). The lack of the C-terminal half of the domain caused the loss of two -sheets and an important disulfide bond that fixed the relative orientation of the N and C terminus. Pro76 was located at a loop position at which a leucine could not be accommodated owing to steric clashes (Figure 1e and f), causing structural changes of the respective loop and/ or decreased protein stability. In the case of p.Arg48Trp, the wild type's arginine formed both cation-pi stacking interactions and a hydrogen bond with Tyr89 ( Figure 1c ). Because of its bulkiness, the side chain of W48 adopted a different orientation in the mutant, resulting in a loss of stabilizing interactions with Tyr89 ( Figure 1d ). Ser113 stabilized the local geometry by a hydrogen bond with Tyr116 that could not be formed in the mutant p.Ser113-Leu (Figure 1g and h). In addition, the Leu113 side chain formed clashes with the side chain of Cys70. Interestingly, the same residue was also affected by clashes upon p.Pro76Leu (Figure 1f ), suggesting similar structural effects.
In contrast, His32 was oriented toward the solvent; therefore, p.His32Arg was not expected to have a significant effect on IL36RA structure/stability, but it possibly has an effect on the interaction with its receptor. As its respective structure is unknown to date, the prediction was based on the crystal structure of the homologous IL-1 in complex with IL1R (Vigers et al., 1997) . Gln32 of IL-1-structurally equivalent to His32 of IL-36RA-formed tight interactions with the IL1 receptor (Figure 1i ), suggesting that the respective residue of IL36RA could also be involved in receptor binding. The structure of the IL1-IL1R complex revealed that residue 48 is also involved in receptor recognition (Figure 1i ), suggesting that mutation p.Arg48Trp not only affects IL36RA stability, but also affects receptor binding. Four online prediction tools support damaging effects of p.Arg48Trp, p.Pro76Leu, and p.Ser113Leu, whereas the rare variant p.His32Arg was predicted to be neutral (Supplementary Table 1 online). Thus, we cannot exclude that p.His32Arg is a rare, non-disease-causing variant. Additional functional validation studies of mutations were beyond the scope of this work.
The mutations, to our knowledge previously unreported, were not present in 190 control individuals from a population group corresponding to/being similar to the carrier's population. All available unaffected parents of patients (five families) tested as heterozygous mutations carriers. In cases of homozygous patients and unavailable parents, quantitative analysis showed no evidence for an undetected intragenic deletion/duplication. The same was true for P08 heterozygous for p.Ser113Leu and 11 patients lacking IL36RN mutations.
The most common European mutation in our and other published cases was p.Ser113Leu. Interestingly, this mutation was also present in P02 with one parent from Iraq. Similarly, p.Pro76-Leu was present in a German/Czech and a Turkish patient. Phenotype-genotype correlation including published cases was difficult owing to different mutations in few carriers. A significant difference in age of onset between carriers of two mutations and noncarriers of mutations was not observed (P ¼ 0.08; excluding P08 (one mutation)). The widely varying age of onset (1-51 years of age) in four homozygous carriers of the most common European mutation p.Ser113Leu (two taken from the previous publication (Onoufriadis et al., 2011) ) can currently not be explained. An additional coding variant (p.Ser200Asn, according to NM_024110) in CARD14, more recently shown to be relevant for the pathogenesis of PsV and GPP (Jordan et al., 2012a, b) , was identified in P02, who developed disease at age 1 year, but not in P05, whose disease manifested at the age of 17 years (Supplementary Table 2 online). p.Ser200Asn was shown to be functionally relevant (Jordan et al., 2012a) and is a potential modifier for disease onset/severity. Sanger sequencing of CARD14 in another 17 patients revealed three rare variants (rare allele o1%) in two patients (Table 1, Supplementary Table 2 online): p.Arg69Gln in P14 is, to our knowledge, a previously unreported variant, also not reported in 4,300 exomes (http://evs.gs.washington.edu/EVS/). Located in the CARD domain, it is predicted to be damaging by various analysis tools. We therefore regard it as a contributing factor to P14's GPP. Described to cause autosomal dominant inherited PsV (Jordan et al., 2012b) , P08's mutation p.Gly117Ser is probably responsible for long-existing PsV, whereas the additional heterozygous IL36RN mutation may have induced his first GPP episode.
Our rate of 38.9% IL36RN mutations provides further evidence that GPP is heterogenous. Anakinra is an effective treatment in some patients with GPP, and treatment success may be related to the presence of IL36RN mutations. As such, revealing the molecular basis of GPP in single patients may be clinically important for therapeutic decision making. 
